Catamaran long-term growth drivers remain intact, says Leerink Leerink views 2014 as a transition year for Catamaran (CTRX) with Cigna (CI) and believes the company is well positioned for the 2015 selling season. The firm think Catamaran's long-term growth drivers are still intact despite its weaker than expected 2014 outlook and keeps an Outperform rating on the stock.
Catamaran to acquire Salveo Specialty Pharmacy for $260M in cash Catamaran announced that it has entered into a definitive agreement to acquire Salveo Specialty Pharmacy, an independent specialty pharmacy company headquartered in St. Petersburg, Florida with business operations in New York and California. Salveo manages approximately $400M in annual drug spend. The purchase price of $260M in cash represents a purchase price multiple of approximately 13x Salveo's trailing-twelve-month EBITDA and is expected to be funded through cash on the balance sheet. This acquisition is expected to be completed during Q4.